Target Price | $14.75 |
Price | $0.69 |
Potential |
2,036.13%
register free of charge
|
Number of Estimates | 4 |
4 Analysts have issued a price target NeuroBo Pharmaceuticals Inc 2026 .
The average NeuroBo Pharmaceuticals Inc target price is $14.75.
This is
2,036.13%
register free of charge
$25.00
3,520.56%
register free of charge
$3.00
334.47%
register free of charge
|
|
A rating was issued by 3 analysts: 3 Analysts recommend NeuroBo Pharmaceuticals Inc to buy, 0 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the NeuroBo Pharmaceuticals Inc stock has an average upside potential 2026 of
2,036.13%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -3.56 | -1.38 |
44.72% | 61.24% | |
P/E | negative |
4 Analysts have issued a NeuroBo Pharmaceuticals Inc forecast for earnings per share. The average NeuroBo Pharmaceuticals Inc EPS is
This results in the following potential growth metrics and future valuations:
NeuroBo Pharmaceuticals Inc...
Analyst | Rating | Action | Date |
---|---|---|---|
Maxim Group |
Locked
➜
Locked
|
Locked | May 19 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 16 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 21 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Dec 30 2024 |
Analyst Rating | Date |
---|---|
Locked
Maxim Group:
Locked
➜
Locked
|
May 19 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 16 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 21 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Dec 30 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.